HTS assays using a disease-relevant cell model for interrogating the MAP kinase pathway initiated by multiple receptors

Assay and Drug Development Technologies

Volumn 6, Issue 3, 2008, Pages 351-359

  Wilkinson, Jennifer M ^a   MacHleidt, Thomas ^a   Echeverria, Victoria M ^a,b   VanDenHeuvel Kramer, Kaitlyn ^a   Honer, Jessica ^a   Zhong, Zhong ^a   Bi, Kun ^a  

^a INVITROGEN CORPORATION   (United States)

^b BellBrook Labs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA LACTAMASE; CL 387785; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; SCATTER FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; 4 ((3 BROMOPHENYL)AMINO) 6,7 DIMETHOXYQUINAZOLINE; 4-((3-BROMOPHENYL)AMINO)-6,7-DIMETHOXYQUINAZOLINE; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR; INDOLE DERIVATIVE; MACROPHAGE STIMULATING PROTEIN; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; RO 31-8220; SCATTER FACTOR; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL ASSAY; CELL LINE; CELL LINE ME 180; CONTROLLED STUDY; ENZYME ACTIVATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIGAND BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VALIDATION STUDY; FEMALE; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTORS, CELL SURFACE;

EID: 51149102706     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2007.117     Document Type: Article

References (16)

1. Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007;6:734-745.
2. Dhillon AS, Hagan S, Rath O, Kolch W: MAP kinase signalling pathway in cancer. Oncogene 2007;26:3279-3290.
3. Roberst, PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310.
4. Kermorgant S, Parker PJ: c-Met signalling. Cell Cycle 2005;4:352-355.
5. Malemud CJ: Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr Opin Pharmacol 2007;7:339-343.
6. O'Grady M, Raha D, Hanson B, Bunting M, Hanson G: Combining RNA interference and kinase inhibitors against cell signaling components involved in cancer. BMC Cancer 2005;5:125-134.
7. Salamanca DA, Khalil RA: Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem Pharmacol 2005;70:1537-1547.
8. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin-6-type cytokine signaling and its regulation. Biochem J 2003;374:1-20.
9. Lichtner RB, Menrad IA, Sommer A, Klar U, Schneider MR: Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001;21:5790-5795.
10. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al.: A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-5469.
11. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-7355.
12. 2 but not tumor necrosis factor. J Biol Chem 2005;280:19036-19044.
13. Johnston PA, Johnston PA: Cellular platforms for HTS: three case studies. Drug Discov Today 2002;7:353-363.
14. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al.: MET amplification leads to gefitinib resistance in lung cancers by activating ERBB3 signaling. Science 2007;316:1039-1041.
15. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng LX, et al.: Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 1998;279:84-88.
16. Peekhaus NT, Ferrer M, Chang T, Kornienko O, Schneeweis JE, Smith TS, et al.: A beta-lactamase-dependent Gal4-estrogen receptor transactivation assay for the ultra-high throughput screening of estrogen receptor agonists in a 3,456-well format. Assay Drug Dev Technol 2003;1:789-800.